Targeting the mitochondria: an exciting new approach to myeloma therapy. Commentary re: N. J. Bahlis et al., Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin. Cancer Res., 8: 3658-3668, 2002.
Dalton
William S
WS
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D005978:Glutathione / Q000378:metabolism; D006801:Humans; D008928:Mitochondria / Q000187:drug effects*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D010087:Oxides / Q000627:therapeutic use*; D017382:Reactive Oxygen Species
D000970:Antineoplastic Agents; D001152:Arsenicals; D004338:Drug Combinations; D010087:Oxides; D017382:Reactive Oxygen Species; D005978:Glutathione; D001205:Ascorbic Acid; D000077237:Arsenic Trioxide